Harler joins IGM as president of autoimmunity and inflammation business
Plus: Precigen, Transition Bio, Shoreline, Syros, Twist, Vor and more
Antibody company IGM Biosciences Inc. (NASDAQ:IGMS) hired Mary Harler as president to lead its autoimmunity and inflammation business unit. Harler was previously an SVP, head of immunology and fibrosis development at Bristol Myers Squibb Co. (NYSE:BMY). John Shiver and Tong-Ming Fu joined as chief strategy officer and CSO of infectious diseases business unit respectively. Shiver was SVP of vaccine R&D and Fu was head of vaccine research, North America at Sanofi (Euronext:SAN; NASDAQ:SNY)
Transition Bio Inc. hired Gregory Miller as CEO and board member, Tuomas Knowles as CTO and Martin Kulander as COO. Miller was CBO at Atalanta Therapeutics and Kulander was senior director of oncology R&D strategy at AstraZeneca plc (LSE:AZN; NASDAQ:AZN). Additionally, Joseph Grosso joined as VP of oncology translation from Bristol Myers Squibb Co. (NYSE:BMY), where he was program lead of Breyanzi...